the melphalan treated patients showed a significantly higher overall objective response frequency ( 59 % ) , according to myeloma task force criteria , when compared to those treated with bcnu ( 40 % ) or ccnu ( 42 % ) .
C0026764
myeloma
C0007257
bcnu